Pharmacodynamic and Therapeutic Pilot Studies of Single-agent Ribavirin in Patients with Human Papillomavirus-related Malignancies

Overview

Journal Oral Oncol

Publisher Elsevier

Specialty Dentistry

Date 2022 Mar 26

PMID 35339025

Authors

Bharat Burman

Scott B Drutman

Matthew G Fury

Richard J Wong

Nora Katabi

Alan L Ho

David G Pfister

Affiliations

Soon will be listed here.

Abstract

Objectives: Ribavirin inhibits eukaryotic translation initiation factor 4E (eIF4E), thereby decreasing cap-dependent translation. In this two-part study, we assessed the pharmacodynamic effects and therapeutic potential of ribavirin in human papillomavirus (HPV)-related malignancies.

Methods: In the pharmacodynamic study, ribavirin (400 mg BID for 14 days) was evaluated in 8 patients with HPV-positive localized oropharyngeal carcinoma with phosphorylated-eIF4E (p-eIF4E) ≥ 30%. In the therapeutic study, ribavirin (1400 mg BID in 28-day cycles, continuously dosed) was evaluated in 12 patients with recurrent and/or metastatic HPV-related cancer. Dose interruptions or reductions were allowed according to prespecified criteria. Toxicities were assessed in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events version 4; response was assessed using Response Evaluation Criteria in Solid Tumors version 1.1. Patients remained on study until disease progression or unacceptable toxicity.

Results: Six patients were evaluable in the pharmacodynamic study: 4 had decreased p-eIF4E after 14 days of ribavirin. In the therapeutic study, 12 patients were evaluable for toxicity, and 9 were evaluable for response. Among these, median follow-up was 3.5 months, and best overall response was stable disease in 5 patients and progression of disease in 4 patients. Median progression-free survival was 1.8 months. The most common treatment-related adverse events (grade > 2) were anemia, dyspnea, and hyperbilirubinemia. All patients had anemia (grades 1-3), with 33% having at least 1 dose reduction.

Conclusion: Oral ribavirin decreases p-eIF4E levels and is well-tolerated. However, a clear signal of efficacy in patients with recurrent and/or metastatic HPV-related cancers was not observed. (NCT02308241, NCT01268579).

Citing Articles

Development of an Intranasal In Situ System for Ribavirin Delivery: In Vitro and In Vivo Evaluation.

Mikhel I, Bakhrushina E, Petrusevich D, Nedorubov A, Appolonova S, Moskaleva N Pharmaceutics. 2024; 16(9).

PMID: 39339163 PMC: 11435039. DOI: 10.3390/pharmaceutics16091125.

eIF4E orchestrates mRNA processing, RNA export and translation to modify specific protein production.

Mars J, Culjkovic-Kraljacic B, Borden K Nucleus. 2024; 15(1):2360196.

PMID: 38880976 PMC: 11185188. DOI: 10.1080/19491034.2024.2360196.

Synthesis methods of 1,2,3-/1,2,4-triazoles: A review.

Dai J, Tian S, Yang X, Liu Z Front Chem. 2022; 10:891484.

PMID: 36226121 PMC: 9548580. DOI: 10.3389/fchem.2022.891484.

References

Siegele B, Cefalu C, Holm N, Sun G, Tubbs J, Meschonat C . eIF4E-targeted suicide gene therapy in a minimal residual mouse model for metastatic soft-tissue head and neck squamous cell carcinoma improves disease-free survival. J Surg Res. 2008; 148(1):83-9. DOI: 10.1016/j.jss.2008.03.011. View

Soulieres D, Licitra L, Mesia R, Remenar E, Li S, Karpenko A . Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1. Clin Cancer Res. 2018; 24(11):2505-2516. DOI: 10.1158/1078-0432.CCR-17-2644. View

Bougie I, Bisaillon M . The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme. J Biol Chem. 2004; 279(21):22124-30. DOI: 10.1074/jbc.M400908200. View

Jhaveri K, Chang M, Juric D, Saura C, Gambardella V, Melnyk A . Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with -Mutant Cancers. Clin Cancer Res. 2020; 27(2):447-459. DOI: 10.1158/1078-0432.CCR-20-2657. View

Pfaendler K, Tewari K . Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol. 2015; 214(1):22-30. PMC: 5613936. DOI: 10.1016/j.ajog.2015.07.022. View

Iglesias-Bartolome R, Martin D, Gutkind J . Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets. Cancer Discov. 2013; 3(7):722-5. PMC: 4348071. DOI: 10.1158/2159-8290.CD-13-0239. View

Lu C, Makala L, Wu D, Cai Y . Targeting translation: eIF4E as an emerging anticancer drug target. Expert Rev Mol Med. 2016; 18:e2. DOI: 10.1017/erm.2015.20. View

McGlennen R, Adams G, Lewis C, Faras A, Ostrow R . Pilot trial of ribavirin for the treatment of laryngeal papillomatosis. Head Neck. 1993; 15(6):504-12; discussion 512-3. DOI: 10.1002/hed.2880150605. View

Jackson R, Hellen C, Pestova T . The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol. 2010; 11(2):113-27. PMC: 4461372. DOI: 10.1038/nrm2838. View

10.

Frenel J, Le Tourneau C, ONeil B, Ott P, Piha-Paul S, Gomez-Roca C . Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017; 35(36):4035-4041. DOI: 10.1200/JCO.2017.74.5471. View

11.

Spangle J, Ghosh-Choudhury N, Munger K . Activation of cap-dependent translation by mucosal human papillomavirus E6 proteins is dependent on the integrity of the LXXLL binding motif. J Virol. 2012; 86(14):7466-72. PMC: 3416298. DOI: 10.1128/JVI.00487-12. View

12.

Larsson O, Li S, Issaenko O, Avdulov S, Peterson M, Smith K . Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res. 2007; 67(14):6814-24. DOI: 10.1158/0008-5472.CAN-07-0752. View

13.

Thorpe L, Yuzugullu H, Zhao J . PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2014; 15(1):7-24. PMC: 4384662. DOI: 10.1038/nrc3860. View

14.

Mantovani F, Banks L . The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene. 2001; 20(54):7874-87. DOI: 10.1038/sj.onc.1204869. View

15.

Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C . A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E. Haematologica. 2014; 100(1):e7-9. PMC: 4281321. DOI: 10.3324/haematol.2014.111245. View

16.

Wendel H, de Stanchina E, Fridman J, Malina A, Ray S, Kogan S . Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004; 428(6980):332-7. DOI: 10.1038/nature02369. View

17.

DeFatta R, Nathan C, De Benedetti A . Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope. 2000; 110(6):928-33. DOI: 10.1097/00005537-200006000-00007. View

18.

Hernando E, Charytonowicz E, Dudas M, Menendez S, Matushansky I, Mills J . The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med. 2007; 13(6):748-53. DOI: 10.1038/nm1560. View

19.

Oridate N, Kim H, Xu X, Lotan R . Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin. Cancer Biol Ther. 2005; 4(3):318-23. DOI: 10.4161/cbt.4.3.1504. View

20.

Coleman L, Peter M, Teall T, Brannan R, Hanby A, Honarpisheh H . Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer. 2009; 100(9):1393-9. PMC: 2694424. DOI: 10.1038/sj.bjc.6605044. View